---
title: "GeneDx - CW27 | 8-K: FY2025 Q3 Revenue: USD 116.74 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263061830.md"
datetime: "2025-10-28T10:45:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263061830.md)
  - [en](https://longbridge.com/en/news/263061830.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263061830.md)
generator: "portal-rs"
---

# GeneDx - CW27 | 8-K: FY2025 Q3 Revenue: USD 116.74 M

Revenue: As of FY2025 Q3, the actual value is USD 116.74 M.

EPS: As of FY2025 Q3, the actual value is USD -0.27.

EBIT: As of FY2025 Q3, the actual value is USD -2.689 M.

### Segment Revenue

-   Total revenue for the third quarter of 2025 was $116.7 million, a 52% increase year-over-year.
-   Exome and genome test revenue was $98.9 million, representing a 65% increase year-over-year.

### Operational Metrics

-   Adjusted gross margin expanded to 74%, up from 64% in the third quarter of 2024.
-   Adjusted net income was $14.7 million, compared to $2.0 million in the third quarter of 2024.
-   GAAP net loss was - $7.6 million.
-   Adjusted total operating expenses for Q3 2025 were $71 million.

### Cash Flow

-   Free cash flow for the third quarter of 2025 was $8.8 million.
-   Cash, cash equivalents, marketable securities, and restricted cash totaled $156.1 million as of September 30, 2025.

### Unique Metrics

-   Exome and genome test volume grew to 25,702, a 33% increase year-over-year.
-   Exome and genome tests accounted for 43% of all tests, up from 33% in the third quarter of 2024.

### Outlook / Guidance

-   GeneDx raised its full-year 2025 revenue guidance to between $425 and $428 million, with expected growth in exome and genome revenue between 53% to 55%.
-   The company anticipates an adjusted gross margin of 70% to 71% and positive adjusted net income each quarter and for the full year.

### Related Stocks

- [WGSWW.US](https://longbridge.com/en/quote/WGSWW.US.md)

## Related News & Research

- [Is Quanta Services (PWR) Trading At A Premium To Fair Value?](https://longbridge.com/en/news/298820833.md)
- [German firms lift China investment as US outlays fall, IW study shows](https://longbridge.com/en/news/298822930.md)
- [3 Beaten-Down Stocks to Buy if There Is a Recession](https://longbridge.com/en/news/298825088.md)
- [L3Harris (LHX) Stock Looks Reasonable Following Its 51% 3 Year Run](https://longbridge.com/en/news/298820997.md)
- [Reliance (RS) Heads To Jefferies Conference Following Demand Led Fair Value Debate](https://longbridge.com/en/news/298815052.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**